Work

Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.6520

Authors: Chris Labaki, Ziad Bakouny, Thibaut Sanglier, Andrew Lachlan Schmidt, Jinjoo Shim, David A. Braun, Fanny Bouquet, Maureen Ann Joyce, Wanling Xie, Sara M. Tolaney, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, F. Hoffmann-La Roche AG, Cairns Hospital, Harvard University, Dana-Farber/Harvard Cancer Center, Roche (France)

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286298694

Cites:

Cited by: 7

Related to: 10